dalteparin has been researched along with Chronic Kidney Failure in 69 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dalteparin and other low-molecular-weight heparins are frequently used for the treatment of deep vein thrombosis and for other indications." | 3.73 | Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. ( Drewe, J; Egger, SS; Krähenbühl, S; Sawatzki, MG, 2005) |
| "Dalteparin 5,000 IU was administered subcutaneously daily for four consecutive days, with HD performed on day 2 and day 4." | 2.72 | A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ( Byrne, S; O'Shea, SI; Ortel, TL; Perry, SL; Szczech, LA, 2006) |
| " The pharmacokinetic model showed that only weight improved the predicted vs observed anti-Xa activity plot." | 2.71 | Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. ( Berland, Y; Brunet, P; Dussol, B; Guillet, B; Lorec-Penet, AM; Portugal, H; Sampol, JJ; Simon, N, 2003) |
| "3% of patients no adverse event was reported." | 2.71 | Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. ( Eckert, M; Hafner, G; Hohmann, V; Klingel, R; Lotz, J; Schwarting, A, 2004) |
| "Patients with end-stage renal disease (ESRD) suffer from high mortality rates of cardiovascular diseases, conditions closely linked to the magnitude of their chronic low-grade inflammation." | 2.71 | Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. ( Gram, J; Jespersen, J; Pedersen, RS; Sjøland, JA, 2005) |
| " SC weight-based dosing on off-dialysis days is a feasible regimen for further clinical thromboprophylaxis efficacy studies in hemodialysis patients." | 2.70 | Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. ( Assaid, CA; Barrett, JS; Cox, DS; Fossler, MJ; Hainer, JW; Hua, TA; Pittenger, AL; Sherrard, DJ; Stephenson, CA; Swan, SK; Williams, RM, 2002) |
| "Dalteparin was initiated and titrated based on clotting score in these patients." | 1.56 | Using dalteparin in quotidian and nocturnal hemodialysis patients: A prospective study. ( Huang, SS; Ke, H; Lindsay, RM; Louzada, M; Muirhead, N; Qi, K; Rehman, F, 2020) |
| " The risk of under dosing seems less predictable; therefore, anti-Xa assay may be useful in severe clinical situations that require higher anticoagulant activity." | 1.48 | Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure? ( Corrà, L; Di Francesco, V; Facchinetti, R; Fantin, F; Fontana, G; Pellizzari, L; Sepe, A; Zamboni, M, 2018) |
| "The sVEGFR-1 level of ESRD group was significantly higher (0." | 1.48 | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications. ( Acar, R; Erturk, I; Ozgurtas, T; Saglam, K; Yesildal, F, 2018) |
| "Dalteparin safety was assessed by monitoring for accumulation, adequate clearance of dalteparin and adverse events." | 1.48 | Dalteparin anticoagulation in paediatric home haemodialysis. ( Hothi, DK; Lutkin, M; Stronach, L; Yadav, P, 2018) |
| "6 IU÷ml was applied, the present dosing method led to over-anticoagulation in more than half of the patients." | 1.42 | Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis. ( van Jaarsveld, BC; Verhave, G; Weijmer, MC, 2015) |
| " In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens." | 1.39 | Use of enoxaparin in end-stage renal disease. ( Coppola, B; Lai, S, 2013) |
| "Usually, the appropriate dosage of low-molecular-weight heparin during haemodialysis is empirically based on the clinical effect." | 1.39 | Pharmacokinetics of dalteparin during haemodialysis. ( de Groot, KA; Grootendorst, DC; Herruer, MH; Koolen, SL; Nigten, J; Schut, NH, 2013) |
| " Neither major adverse events nor major hemorrhages were reported Prolonged activated partial thromboplastin times (aPTT) at 30 minutes after hemodialysis were reported in two cases." | 1.37 | Efficacy and safety of enoxaparin during hemodialysis: results from the HENOX study. ( Bannachak, D; Chittinandana, A; Kanjanakul, I; Krairittichai, U; Sumethkul, V; Thitiarchakul, S; Vareesangthip, K, 2011) |
| "Important CKD disagreements occur in approximately 20% of acute coronary syndrome patients, affecting dosing adjustments in those already susceptible to bleeding." | 1.35 | Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. ( Alexander, KP; Chen, AY; Gibler, WB; Harrington, RA; Melloni, C; Newby, LK; Ohman, EM; Peterson, ED; Roe, MT; Spinler, SA; Szczech, LA, 2008) |
| "Therapeutically dosed dalteparin accumulates in patients with severe RI (group C)." | 1.35 | Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ( Brodmann, D; Fischer, AG; Odermatt, Y; Schmid, P; Wuillemin, WA, 2009) |
| "Patients with end-stage renal disease (ESRD) who receive enoxaparin are at increased risk for adverse bleeding episodes." | 1.33 | Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. ( Best, AM; Brophy, DF; Carr, ME; Gehr, TW; Martin, EJ; Paul, K, 2006) |
| " Maximum A Posteriori Bayesian (MAPB) priors were developed by pharmacokinetic analysis." | 1.33 | Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease. ( Brophy, DF; Overholser, BR; Sowinski, KM, 2006) |
| "Subjects with ESRD had an approximately 50% greater anticoagulant effect, determined by thrombin generation time prolongation, than controls at antifactor Xa activity concentrations of 0." | 1.32 | Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. ( Brophy, DF; Carr, ME; Gehr, TW; Martin, EJ, 2004) |
| "Patients with chronic renal failure and hyperphosphatemia may be predisposed to develop calcinosis cutis." | 1.31 | Nadroparin-induced Calcinosis cutis in renal transplant recipients. ( Hilbrands, LB; Ruiter, DJ; van Haren, FM, 2001) |
| "Prospective, single-dose pharmacokinetic study." | 1.31 | The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. ( Brophy, DF; Comstock, TJ; Gehr, TW; Venitz, J; Wazny, LD, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (7.25) | 18.2507 |
| 2000's | 44 (63.77) | 29.6817 |
| 2010's | 17 (24.64) | 24.3611 |
| 2020's | 3 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Verhave, G | 1 |
| Weijmer, MC | 1 |
| van Jaarsveld, BC | 1 |
| Rydzewska-Rosołowska, A | 1 |
| Borawski, J | 2 |
| Myśliwiec, M | 3 |
| Kamper, AM | 1 |
| Lins, RL | 1 |
| Zachée, P | 1 |
| Van Bergen, S | 1 |
| Hosten, S | 1 |
| Daelemans, R | 1 |
| Wanic-Kossowska, M | 1 |
| Kozioł, L | 1 |
| Roszkowiak, B | 1 |
| Lacka, M | 1 |
| Frankiewicz, D | 1 |
| Mandel, M | 1 |
| van Haren, FM | 1 |
| Ruiter, DJ | 1 |
| Hilbrands, LB | 1 |
| Reach, I | 1 |
| Luong, N | 1 |
| Chastang, C | 1 |
| Chakroun, M | 1 |
| Mirshahi, S | 1 |
| Mirshahi, MC | 1 |
| Soria, J | 1 |
| Desmichels, D | 1 |
| Baumelou, A | 1 |
| Batt, TJ | 1 |
| Lincz, LF | 1 |
| Prasad, R | 1 |
| Patel, RP | 1 |
| Shastri, M | 1 |
| Lioufas, N | 1 |
| Smith, AG | 1 |
| Jose, MD | 1 |
| Mattioli, M | 1 |
| Benfaremo, D | 1 |
| Mancini, M | 1 |
| Mucci, L | 1 |
| Mainquà, P | 1 |
| Polenta, A | 1 |
| Baldini, PM | 1 |
| Fulgenzi, F | 1 |
| Dennetta, D | 1 |
| Bedetta, S | 1 |
| Gasperoni, L | 1 |
| Caraffa, A | 1 |
| Frausini, G | 1 |
| Pellizzari, L | 1 |
| Facchinetti, R | 1 |
| Corrà, L | 1 |
| Sepe, A | 1 |
| Fantin, F | 1 |
| Fontana, G | 1 |
| Zamboni, M | 1 |
| Di Francesco, V | 1 |
| Erturk, I | 1 |
| Yesildal, F | 1 |
| Acar, R | 1 |
| Ozgurtas, T | 1 |
| Saglam, K | 1 |
| Aniort, J | 1 |
| Piraud, A | 1 |
| Adda, M | 1 |
| Perreira, B | 1 |
| Bouiller, M | 1 |
| Fourcade, J | 1 |
| Guerraoui, A | 1 |
| Kalbacher, E | 1 |
| Krumel, T | 1 |
| Moragues, HL | 1 |
| Thibaudin, D | 1 |
| Vela, CG | 1 |
| Vernin, G | 1 |
| Weclawiak, H | 1 |
| Bernard, L | 1 |
| Heng, AE | 1 |
| Souweine, B | 1 |
| Chan, KE | 1 |
| Thadhani, RI | 1 |
| Maddux, FW | 1 |
| Naumnik, B | 3 |
| Koc-Żórawska, E | 1 |
| Lai, S | 1 |
| Coppola, B | 1 |
| Christidou, F | 1 |
| Bamichas, G | 1 |
| Galaktidou, G | 1 |
| Fragidis, S | 1 |
| Gionanlis, L | 1 |
| Frangia, T | 1 |
| Bischiniotis, T | 1 |
| Sombolos, K | 1 |
| Saland, JM | 1 |
| Shneider, BL | 1 |
| Bromberg, JS | 1 |
| Shi, PA | 1 |
| Ward, SC | 1 |
| Magid, MS | 1 |
| Benchimol, C | 1 |
| Seikaly, MG | 1 |
| Emre, SH | 1 |
| Bresin, E | 1 |
| Remuzzi, G | 1 |
| Albaladejo, P | 1 |
| Varela Rois, P | 1 |
| González García, J | 1 |
| Pérez Rodríguez, MT | 1 |
| Paseiro García, MJ | 1 |
| Carcacía Hermilla, ID | 1 |
| Fernández-Ruiz, M | 1 |
| Guerra-Vales, JM | 1 |
| Vega S, J | 1 |
| Martínez R, G | 1 |
| Goecke S, H | 1 |
| Vareesangthip, K | 1 |
| Thitiarchakul, S | 1 |
| Kanjanakul, I | 1 |
| Sumethkul, V | 1 |
| Krairittichai, U | 1 |
| Chittinandana, A | 1 |
| Bannachak, D | 1 |
| Polkinghorne, KR | 1 |
| McMahon, LP | 1 |
| Becker, GJ | 1 |
| Olszowska, A | 1 |
| Zelichowski, G | 1 |
| Lavaud, S | 1 |
| Canivet, E | 1 |
| Wuillai, A | 1 |
| Maheut, H | 1 |
| Randoux, C | 1 |
| Bonnet, JM | 1 |
| Renaux, JL | 1 |
| Chanard, J | 1 |
| Guillet, B | 1 |
| Simon, N | 1 |
| Sampol, JJ | 1 |
| Lorec-Penet, AM | 1 |
| Portugal, H | 1 |
| Berland, Y | 1 |
| Dussol, B | 1 |
| Brunet, P | 1 |
| Klingel, R | 2 |
| Schaefer, M | 1 |
| Schwarting, A | 2 |
| Himmelsbach, F | 1 |
| Altes, U | 1 |
| Uhlenbusch-Körwer, I | 1 |
| Hafner, G | 2 |
| Thorevska, N | 1 |
| Amoateng-Adjepong, Y | 1 |
| Sabahi, R | 1 |
| Schiopescu, I | 1 |
| Salloum, A | 1 |
| Muralidharan, V | 1 |
| Manthous, CA | 1 |
| Brophy, DF | 7 |
| Martin, EJ | 4 |
| Gehr, TW | 5 |
| Carr, ME | 4 |
| Lotz, J | 1 |
| Eckert, M | 1 |
| Hohmann, V | 1 |
| Best, AM | 2 |
| Malik, A | 1 |
| Capling, R | 1 |
| Bastani, B | 1 |
| Weinsheimer, RL | 1 |
| Libby, E | 1 |
| Howdieshell, TR | 1 |
| Kruzel-Davila, E | 1 |
| Frajewicki, V | 1 |
| Kushnir, D | 1 |
| Eyal, A | 1 |
| Kohan, R | 1 |
| Isla, A | 1 |
| Gascón, AR | 1 |
| Maynar, J | 1 |
| Arzuaga, A | 1 |
| Corral, E | 1 |
| Martín, A | 1 |
| Solinís, MA | 1 |
| Muñoz, JL | 1 |
| Paul, K | 1 |
| Venitz, J | 2 |
| Overholser, BR | 1 |
| Sowinski, KM | 1 |
| Pawlak, K | 1 |
| Mys'liwiec, M | 1 |
| Sica, DA | 1 |
| Melloni, C | 1 |
| Peterson, ED | 1 |
| Chen, AY | 1 |
| Szczech, LA | 2 |
| Newby, LK | 1 |
| Harrington, RA | 1 |
| Gibler, WB | 1 |
| Ohman, EM | 1 |
| Spinler, SA | 1 |
| Roe, MT | 1 |
| Alexander, KP | 1 |
| Przedlacki, J | 1 |
| Bogdańska-Straszyńska, B | 1 |
| Sawicka, B | 1 |
| Włodarczyk, D | 1 |
| Sladowska, B | 1 |
| Ajewski, M | 1 |
| Wasiak, K | 1 |
| Gellert, R | 1 |
| Wazny, LD | 1 |
| Comstock, TJ | 1 |
| Kalus, JS | 1 |
| Spencer, AP | 1 |
| Lile, J | 1 |
| Huang, SS | 1 |
| Qi, K | 1 |
| Louzada, M | 1 |
| Lindsay, RM | 1 |
| Rehman, F | 1 |
| Ke, H | 1 |
| Muirhead, N | 1 |
| Lutkin, M | 1 |
| Stronach, L | 1 |
| Yadav, P | 1 |
| Hothi, DK | 1 |
| Nigten, J | 1 |
| de Groot, KA | 1 |
| Grootendorst, DC | 1 |
| Koolen, SL | 1 |
| Herruer, MH | 1 |
| Schut, NH | 1 |
| Nassiri, AA | 1 |
| Hakemi, MS | 1 |
| Soulati, M | 1 |
| Marashian, M | 1 |
| Rahbar, K | 1 |
| Azizi, F | 1 |
| Schmid, P | 1 |
| Brodmann, D | 1 |
| Odermatt, Y | 1 |
| Fischer, AG | 1 |
| Wuillemin, WA | 1 |
| Schött, U | 1 |
| Nilsson, LG | 1 |
| Broman, M | 1 |
| Engström, M | 1 |
| Hiwatashi, A | 1 |
| Usui, JI | 1 |
| Sato, C | 1 |
| Hasegawa, Y | 1 |
| Yamagata, K | 1 |
| Rodger, MA | 1 |
| Ramsay, T | 1 |
| MacKinnon, M | 1 |
| Westphal, M | 1 |
| Wells, PS | 1 |
| McCormick, B | 1 |
| Knoll, G | 1 |
| Egger, SS | 1 |
| Sawatzki, MG | 1 |
| Drewe, J | 1 |
| Krähenbühl, S | 1 |
| Attman, PO | 1 |
| Ottosson, P | 1 |
| Samuelsson, O | 1 |
| Eriksson, UG | 1 |
| Eriksson-Lepkowska, M | 1 |
| Fager, G | 1 |
| Ziai, F | 1 |
| Benesch, T | 1 |
| Kodras, K | 1 |
| Neumann, I | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Gritters, M | 1 |
| Grooteman, MP | 1 |
| Schoorl, M | 2 |
| Bartels, PC | 1 |
| Scheffer, PG | 1 |
| Teerlink, T | 1 |
| Schalkwijk, CG | 1 |
| Spreeuwenberg, M | 1 |
| Nubé, MJ | 1 |
| Kozlova, TV | 1 |
| Shilo, VIu | 1 |
| Denisov, AIu | 1 |
| Perry, SL | 1 |
| O'Shea, SI | 1 |
| Byrne, S | 1 |
| Ortel, TL | 1 |
| Kerr, PG | 1 |
| Mattingly, S | 1 |
| Lo, A | 1 |
| Atkins, RC | 1 |
| Hofbauer, R | 1 |
| Moser, D | 1 |
| Frass, M | 1 |
| Oberbauer, R | 1 |
| Kaye, AD | 1 |
| Wagner, O | 1 |
| Kapiotis, S | 1 |
| Druml, W | 1 |
| Neuhaus, TJ | 1 |
| Goetschel, P | 1 |
| Schmugge, M | 1 |
| Leumann, E | 1 |
| Mahmood, D | 1 |
| Makoveichuk, E | 1 |
| Nilsson, S | 1 |
| Olivecrona, G | 1 |
| Stegmayr, B | 1 |
| Dhondt, A | 1 |
| Pauwels, R | 1 |
| Devreese, K | 1 |
| Eloot, S | 1 |
| Glorieux, G | 1 |
| Vanholder, R | 1 |
| Hainer, JW | 1 |
| Sherrard, DJ | 1 |
| Swan, SK | 1 |
| Barrett, JS | 1 |
| Assaid, CA | 1 |
| Fossler, MJ | 1 |
| Cox, DS | 1 |
| Williams, RM | 1 |
| Pittenger, AL | 1 |
| Stephenson, CA | 1 |
| Hua, TA | 1 |
| Sarris, E | 1 |
| Tsele, E | 1 |
| Bagiatoudi, G | 1 |
| Salpigidis, K | 1 |
| Stavrianaki, D | 1 |
| Kaklamanis, L | 1 |
| Siakotos, M | 1 |
| Sjøland, JA | 1 |
| Pedersen, RS | 1 |
| Jespersen, J | 1 |
| Gram, J | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| d'Urso, M | 1 |
| Laurent, M | 1 |
| Gaussem, P | 1 |
| Février, M | 1 |
| Durand-Gasselin, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Evaluation of the Efficacy of an inTerdialytic Ethanol 40% v/v - enoxapaRin 1000 U/mL Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients: a mulTi-centre, Randomized, Single Blind, Parallel Group studY (ETERNITY)"[NCT03083184] | Phase 3 | 400 participants (Anticipated) | Interventional | 2018-02-09 | Recruiting | ||
| Pilot, Prospective, Multicenter, Open and Non-randomised Study: Definition of an Index of Anti Xa Value at the End of Hemodialysis Treatment.[NCT00781690] | 53 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function[NCT00264693] | 96 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration[NCT00583765] | 20 participants (Actual) | Observational | 2005-04-30 | Completed | |||
| The Use of Low Molecular Weight Heparin in Hemodiafiltration[NCT00756145] | Phase 4 | 15 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dalteparin and Chronic Kidney Failure
| Article | Year |
|---|---|
[Are low-molecular-weight heparins safe in patients with chronic kidney disease?].
Topics: Anticoagulants; Contraindications; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Kidney Failure | 2010 |
[Enoxaparin in haemodialysis].
Topics: Anticoagulants; Enoxaparin; Fibrinolytic Agents; Humans; Kidney Failure, Chronic; Renal Dialysis; Th | 2002 |
Use of enoxaparin in patients with chronic kidney disease: safety considerations.
Topics: Animals; Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hemorrhage; Humans; Kidney Failure, C | 2007 |
25 trials available for dalteparin and Chronic Kidney Failure
| Article | Year |
|---|---|
Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.
Topics: Activins; Aged; Cross-Over Studies; Dalteparin; Enoxaparin; Female; Follistatin; Heparin, Low-Molecu | 2009 |
Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients.
Topics: Drug Combinations; Humans; Kidney Failure, Chronic; Nadroparin; Platelet Aggregation Inhibitors; Ren | 1997 |
Dose effect relationship of reviparin in chronic hemodialysis: a crossover study versus nadroparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Cross-Over Studies; Dose-Response | 2001 |
Evaluation of the efficacy of an interdialytic "ethanol 40% v/v - enoxaparin 1000 U/mL" lock solution to prevent tunnelled catheter infections in chronic hemodialysis patients: a multi-centre, randomized, single blind, parallel group study.
Topics: Adult; Anti-Infective Agents, Local; Catheter-Related Infections; Catheters, Indwelling; Clinical Tr | 2019 |
Over-dialysis plasma RANTES increase depends on heparin dose and cardiovascular disease status.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Appointments and Schedules; Atherosclerosis; Chemoki | 2013 |
Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Drug Administration Schedule; Enoxap | 2008 |
Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Topics: Anticoagulants; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Enoxaparin; Factor Xa Inhibitors | 2002 |
Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Topics: Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; | 2003 |
Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Injections, Intraveno | 2003 |
Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Kidney Failur | 2004 |
The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
Topics: Adult; Anticoagulants; Blood Coagulation; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Female; | 2006 |
Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
Topics: Aged; Anticoagulants; E-Selectin; Enoxaparin; Female; Heparin; Humans; Intercellular Adhesion Molecu | 2009 |
[Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Enoxaparin; Extracorporeal Circulation; Female; He | 1994 |
Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
Topics: Adult; Aged; Anticoagulants; Aryldialkylphosphatase; Dalteparin; Drug Costs; Female; Heparin; Humans | 2009 |
Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Cross-Over Studies; | 2010 |
Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Topics: Aged; Aged, 80 and over; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2012 |
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; G | 2005 |
The effect of oral anticoagulation on clotting during hemodialysis.
Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation; Cross-Over Studies; Dalteparin; Drug | 2005 |
Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Cell Degranulation; Cholesterol, LD | 2006 |
A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Body Weight; Dalteparin; Drug Admi | 2006 |
Effect of anticoagulation on blood membrane interactions during hemodialysis.
Topics: Adult; Anticoagulants; Blood Coagulation; Cell Adhesion; Citrates; Dalteparin; Erythrocytes; Female; | 1999 |
Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial.
Topics: Anticoagulants; beta 2-Microglobulin; Blood Coagulation; Cross-Over Studies; Factor Xa Inhibitors; F | 2015 |
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Topics: Adolescent; Adult; Aged; Antithrombin III; Biomarkers; Blood Coagulation; Cross-Over Studies; Dizzin | 2002 |
Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients.
Topics: Adult; Aged; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Fibrin; Fibrin Fib | 2005 |
[Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Creatinine; Drug Administration Sched | 2001 |
41 other studies available for dalteparin and Chronic Kidney Failure
| Article | Year |
|---|---|
Anticoagulation with dalteparin and nadroparin in nocturnal haemodialysis.
Topics: Anticoagulants; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug; Female; Follow-Up S | 2015 |
[Calcified subcutaneous nodules in patients with chronic renal failure as a result of injections with nadroparin (Fraxiparine)].
Topics: Aged; Anticoagulants; Arteriosclerosis; Calcinosis; Female; Humans; Hypertension; Injections, Subcut | 1998 |
Nadroparin-induced Calcinosis cutis in renal transplant recipients.
Topics: Adult; Biopsy; Calcinosis; Calcium; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 2001 |
Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Kinetics; | 2020 |
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
Topics: Aged; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; Enoxaparin; Female; Follow-Up Studies; H | 2021 |
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2018 |
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Cardiovascu | 2018 |
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; E | 2013 |
Use of enoxaparin in end-stage renal disease.
Topics: Enoxaparin; Female; Hemorrhage; Heparin; Humans; Kidney Failure, Chronic; Male; Venous Thromboemboli | 2013 |
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.
Topics: Anticoagulants; Child, Preschool; Complement Factor H; Enoxaparin; Hemolytic-Uremic Syndrome; Hetero | 2009 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
[Subdural spinal hematoma and intraventricular bleeding after lumbar puncture].
Topics: Aged; Anticoagulants; Back Pain; Cerebral Hemorrhage; Cerebral Ventricles; Enoxaparin; Fatal Outcome | 2009 |
Enoxaparin-induced retroperitoneal haematoma in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hematoma; Humans; Kidney Failure, Chron | 2010 |
Efficacy and safety of enoxaparin during hemodialysis: results from the HENOX study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Catheters, Indwelling; Enox | 2011 |
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Topics: Acrylic Resins; Animals; Anticoagulants; Biocompatible Materials; Disease Models, Animal; Dose-Respo | 2003 |
Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biocompatible Materials; Blood Coagulation; Blood Co | 2004 |
Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Glomerular Filtration Rate; Hemorrhage; Heparin; Hospitali | 2004 |
Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chronic Disease; Enoxaparin; Fact | 2004 |
Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Blood Platelets; Chronic Disease; Dose-Response Rela | 2004 |
Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematoma; Humans; Kidney Failure, Chronic; Middle Aged; Re | 2005 |
Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin.
Topics: Abdominal Injuries; Abdominal Wall; Accidents, Traffic; Adult; Anticoagulants; Enoxaparin; Epigastri | 2005 |
Retroperitoneal hematoma in a hemodialysis patient receiving low molecular weight heparin.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematoma; Humans; Kidney Failure, Chronic; Renal Dialysis; | 2005 |
In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
Topics: Acrylonitrile; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; He | 2005 |
Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease.
Topics: Adult; Antithrombin III; Blood Coagulation Tests; Case-Control Studies; Enoxaparin; Female; Fibrinol | 2006 |
Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease.
Topics: Adult; Antithrombin III; Blood Specimen Collection; Enoxaparin; Female; Humans; Kidney Failure, Chro | 2006 |
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Creatinine; Enoxaparin; Female; Fibrinolytic Agents; Glo | 2008 |
The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
Topics: Adult; Anticoagulants; Area Under Curve; Enoxaparin; Factor Xa; Female; Humans; Injections, Subcutan | 2001 |
Enoxaparin should be used cautiously in patients with end-stage renal disease.
Topics: Anticoagulants; Enoxaparin; Humans; Kidney Failure, Chronic; Reproducibility of Results | 2001 |
Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.
Topics: Anticoagulants; Blood Transfusion; Enoxaparin; Hemorrhage; Humans; Kidney Diseases; Kidney Failure, | 2001 |
Using dalteparin in quotidian and nocturnal hemodialysis patients: A prospective study.
Topics: Anticoagulants; Dalteparin; Female; Hemodialysis, Home; Humans; Kidney Failure, Chronic; Male; Middl | 2020 |
Dalteparin anticoagulation in paediatric home haemodialysis.
Topics: Adolescent; Age Factors; Anticoagulants; Blood Coagulation; Child; Child, Preschool; Dalteparin; Dos | 2018 |
Pharmacokinetics of dalteparin during haemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Follow-Up Studies; Humans; Injections, | 2013 |
Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtra | 2009 |
Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtra | 2009 |
Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtra | 2009 |
Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Glomerular Filtra | 2009 |
Induction of hemodialysis therapy in a case with factor XIII deficiency.
Topics: Catheters, Indwelling; Dalteparin; Diabetic Nephropathies; Factor XIII Deficiency; Female; Fibrinoly | 2011 |
Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Hematoma; Heparin Antagonists; Humans; | 2005 |
[Use of fragmin in program hemodialysis of patients with terminal chronic renal failure].
Topics: Adult; Antibodies; Dalteparin; Factor Xa; Female; Fibrinolytic Agents; Humans; Infusion Pumps, Impla | 2005 |
The adequacy of fragmin as a single bolus dose with reused dialyzers.
Topics: Adult; Aged; Dalteparin; Equipment Reuse; Hemodialysis Solutions; Heparin; Humans; Kidney Failure, C | 1994 |
Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid.
Topics: Adolescent; Anticoagulants; Child; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinat | 2000 |
Response of angiopoietin-like proteins 3 and 4 to hemodialysis.
Topics: Aged; Angiopoietin-Like Protein 1; Angiopoietin-like Proteins; Angiopoietins; Case-Control Studies; | 2014 |
Tinzaparin: excess mortality in elderly patients with renal failure. Unfractionated heparin is best in this setting.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Fibrinolytic Agents; Heparin; Heparin, Low-Molecu | 2009 |
Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin.
Topics: Aged; Alopecia; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Kidney Failure, Chronic; | 2003 |